Title Reaching out to the UNdiagnosed people infected with blood-borne viral infections (RUNtoBBV) Objectives 1. To study the efficacy of an outreach methodology to increase the uptake for screening, linkage to care and treatment in (active or former) people who use drugs (PWUD) Trial design Prospective multicenter interventional cohort design Number of subjects 336 inclusions (with prevalence of HCV Ab: 30%) * 168 Antwerp * 168 Limburg Selection criteria Inclusion criteria: * 18 years of age * History of/ or active drug use * Written informed consent obtained Exclusion criteria * Currently enrolled in centralized OST program of Free Clinic or CAD Limburg Endpoints The following endpoints will be compared between the centers in Limburg and Antwerp: (Main outcome in bold) Main objectives: * Prevalence of blood-borne viral infections in Belgian (former or active) PWUD: * HCV infection (number of HCV Ab+ / number of screened PWUD) * HBV infection (number of HBsAg+/number of screened PWUD) * HIV infection (number of HIV Ab+/number of screened PWUD) * Analysis of linkage to care to hepatologist/ infectiologist (number of patients who adhered to their consultation/number of referred patients) Secondary objectives: * Analysis of risk behavior/sociodemographics linked to presence of BBV infections * Analysis of uptake of anti(retro)viral treatment (number of patients started on treatment/number of patients needing treatment) * Analysis of treatment adherence (adherence to treatment consultations/total planned consultations) * Analysis of treatment outcome (total number of cured or virally suppressed patients/total number of treated patients)
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
HCV Ab+ (Hepatitis C Virus antibody)
Timeframe: day 1
HBsAg+ (Hepatitis B surface Antigen)
Timeframe: day 1
HIV Ab+ (human immunodeficiency virus) antibody
Timeframe: day 1